Linked Peptides Inhibit HIV Entry via gp41 N-trimer Pocket
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HIV entry inhibitors, such as Fuzeon, face limitations including high dosing requirements, high cost, and the emergence of resistant strains, while D-peptides have theoretical advantages like protease resistance and oral bioavailability but have not been fully realized due to limited potency and toxicity issues.
Innovation Solution
Development of isolated compositions comprising two or more linked peptides that interact with the N-trimer pocket of the viral transmembrane protein gp41, including peptides less than 10 amino acid residues in length, to inhibit viral entry into cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Fuzeon (T-20) is used as an HIV entry inhibitor, then viral entry is inhibited, but high dosing requirements and high cost are incurred
Solution Approach 1:
The C-peptide is divided into multiple segments (e.g., first C-peptide segment and second C-peptide segment) that can be combined in various ways to create multiple inhibitor variants. This segmentation allows for optimization of dosing requirements while maintaining viral entry inhibition, as different segment combinations can be tailored to achieve potent activity at lower doses.
Solution Approach 2:
The invention modifies parameters of the C-peptide structure including truncation to specific residue ranges (e.g., residues 642-673, 642-669, 650-673), amino acid substitutions, and N-terminal modifications. These parameter changes optimize the balance between potency (reducing dosing requirements) and stability, allowing the inhibitor to maintain effectiveness at lower doses.
2Reliability
If Fuzeon (T-20) is used as an HIV entry inhibitor, then viral entry is inhibited, but high cost is incurred
Solution Approach 1:
The invention uses truncated C-peptide segments (shorter than the full 36-residue T-20) that can be synthesized more economically. These shorter peptide segments maintain sufficient antiviral activity while reducing manufacturing complexity and cost, making the therapy more accessible without sacrificing viral entry inhibition.
Solution Approach 2:
By segmenting the C-peptide into modular units that can be independently synthesized and then combined, the invention enables more efficient manufacturing processes. This modular approach reduces production costs compared to synthesizing the full-length peptide, while maintaining the reliability of viral entry inhibition through optimized segment combinations.
3Reliability
If Fuzeon (T-20) is used as an HIV entry inhibitor, then viral entry is inhibited, but resistant strains emerge
Solution Approach 1:
The invention creates a family of C-peptide inhibitor variants with different sequences and structures that all target the same gp41 N-trimer pocket. This multi-functionality approach means that if resistance develops to one variant, other variants in the family can still effectively inhibit viral entry, preventing the emergence of resistant strains while maintaining reliable inhibition.
Solution Approach 2:
By systematically varying parameters such as amino acid substitutions (e.g., W650L, W650F mutations), truncation points, and N-terminal modifications across multiple inhibitor variants, the invention creates diversity in the inhibitor family. This parameter variation ensures that resistant strains cannot easily adapt to all variants simultaneously, maintaining reliable viral entry inhibition over time.
4Stability of the object's composition
If D-peptides are used to inhibit viral entry, then protease resistance is achieved, but limited potency and toxicity issues remain
Solution Approach 1:
The invention creates composite peptide structures by combining D-amino acid residues (for protease resistance) with L-amino acid residues (for maintaining natural binding conformation and potency). This composite approach allows the peptide to achieve both protease stability and high potency with improved toxicity profile, as the D-L hybrid structure leverages the advantages of both stereoisomers.
Solution Approach 2:
The invention applies D-amino acid substitutions at specific local positions within the C-peptide sequence where protease susceptibility is highest, while maintaining L-amino acids in regions critical for binding affinity and activity. This localized application of D-amino acids provides protease resistance without compromising potency or introducing toxicity, optimizing the overall peptide performance.
Data Source
AI summary
Disclosed are compositions and methods for inhibiting viral entry.